Search

Your search keyword '"Schmidt, Warren"' showing total 192 results
Start Over Author "Schmidt, Warren" Publication Type Academic Journals
192 results on '"Schmidt, Warren"'

1. Modification of the third phase in the framework for vertebrate species persistence in urban mosaic environments

Author

Downs, Colleen T., Alexander, Jarryd, Brown, Mark, Chibesa, Moses, Ehlers Smith, Yvette C., Gumede, S. Thobeka, Hart, Lorinda, Josiah, Kyrone K., Kalle, Riddhika, Maphalala, Machawe, Maseko, Mfundo, McPherson, Shane, Ngcobo, Samukelisiwe P., Patterson, Lindsay, Pillay, Kerushka, Price, Cormac, Raji, Islamiat Abidemi, Ramesh, Tharmalingam, Schmidt, Warren, Senoge, Ntaki D., Shivambu, Tinyiko C., Shivambu, Ndivhuwo, Singh, Nikisha, Singh, Preshnee, Streicher, Jarryd, Thabethe, Vuyisile, Thatcher, Harriet, Widdows, Craig, Wilson, Amy-Leigh, Zungu, Manqoba M., and Ehlers Smith, David A.

Published
2021
Full Text
View/download PDF

2. Correction to: Modification of the third phase in the framework for vertebrate species persistence in urban mosaic environments

Author

Downs, Colleen T., Alexander, Jarryd, Brown, Mark, Chibesa, Moses, Ehlers Smith, Yvette C., Gumede, S. Thobeka, Hart, Lorinda, Josiah, Kyrone K., Kalle, Riddhika, Maphalala, Machawe, Maseko, Mfundo, McPherson, Shane, Ngcobo, Samukelisiwe P., Patterson, Lindsay, Pillay, Kerushka, Price, Cormac, Raji, Islamiat Abidemi, Ramesh, Tharmalingam, Schmidt, Warren, Senoge, Ntaki D., Shivambu, Tinyiko C., Shivambu, Ndivhuwo, Singh, Nikisha, Singh, Preshnee, Streicher, Jarryd, Thabethe, Vuyisile, Thatcher, Harriet, Widdows, Craig, Wilson, Amy-Leigh, Zungu, Manqoba M., and Ehlers Smith, David A.

Published
2021
Full Text
View/download PDF

3. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Author

Gadano, Adrian, Martins, Marcelo, Angus, Peter, Bate, John, Danta, Mark, George, Jacob, Hodge, Alexander, Kontorinis, Nickolas, Roberts, Stuart, Sanagapalli, Santosh, Skoien, Richard, Thompson, Alexander, Zekry, Amany, Stauber, Rudolf, Trauner, Michael, Moreno, Christophe, Reynaert, Hendrik, Verbeke, Len, Silva, Mario Reis Alvares da, Parise, Edison, Oliveira, Claudia Pinto Marques Souza de, Araujo, Roberta Chaves, Martinelli, Ana de Lourdes Candolo, Borman, Meredith, Chandok, Natasha, Elkhashab, Magdy, Fraser, Hughie, Kaita, Kelly, Ma, Mang, Marotta, Paul, Ramji, Alnoor, Tam, Edward, Yoshida, Eric, Swain, Mark, Sebastiani, Giada, Petrunia, Denis, Abergel, Armando, Anty, Rodolphe, Bourlière, Marc, Boursier, Jérôme, Bureau, Christophe, Castera, Laurent, Habersetzer, François, Hézode, Christophe, Ledinghen, Victor De, Leroy, Vincent, Loustaud-Ratti, Véronique, Mathurin, Philippe, Pol, Stanislas, Zoulim, Fabien, Hinrichsen, Holger, Ingiliz, Patrick, Lammert, Frank, Manns, Michael, Schattenberg, Jörn, Schiefke, Ingolf, Trautwein, Christian, Zeuzem, Stefan, Hui, Aric, Li, King-Kong, Wong, Vincent, Acharya, Subrat, Chowdhury, Abhijit, Duseja, Ajay, Kapoor, Dharmesh, Mukewar, Shrikant, Sarin, Shiv, Shah, Samir, Shalimar, Sood, Ajit, Tantry, BV, Ben-Ari, Ziv, Katchman, Helena, Safadi, Rifaat, Veitsman, Ella, Zuckerman, Eli, Brunetto, Maurizia, Lampertico, Pietro, Mangia, Alessandra, Akahane, Takemi, Akuta, Norio, Eguchi, Yuichiro, Fujiyama, Shigetoshi, Genda, Takuya, Hiasa, Yoichi, Ido, Akio, Ikeda, Fusao, Ikegami, Tadashi, Imajo, Kento, Itoh, Yoshito, Iwasa, Motoh, Karino, Yoshiyasu, Kato, Naoya, Kawaguchi, Takumi, Kawanaka, Miwa, Kido, Masahiro, Kobayashi, Tomoo, Kurosaki, Masayuki, Matsuzaki, Yasushi, Mita, Eiji, Mizukoshi, Eishiro, Nakahara, Takashi, Nomura, Hideyuki, Notsumata, Kazuo, Okanoue, Takeshi, Saito, Satoshi, Sakugawa, Hiroshi, Suzuki, Yoshiyuki, Takaguchi, Koichi, Takaki, Akinobu, Takashima, Tomoyuki, Tanaka, Saiyu, Tsuji, Keiji, Ueno, Yoshiyuki, Umemura, Takeji, Uto, Hirofumi, Yamashita, Nobuyuki, Yanase, Mikio, Yatsuhashi, Hiroshi, Yoneda, Masashi, Chan, Wah Kheong, Tan, Soek Siam, Garza, Laura Cisneros, Ladron De Guevara Cetina, Alma, Angeles, Rocio Guadalupe Vargas, Silva, Francisca Martinez, Van Erpecum, Karel, Orr, David, Jabłkowski, Maciej, Jaroszewicz, Jerzy, Ramos, Jose, Ahmed, Taufique, Ang, Tiing, Dan, Yock young, Goh, Boon Bee, Kaliyaperumal, Kalaiyarasi, Yip, Cherng Hann, Baik, Soon Koo, Jang, Byoung Kuk, Jun, Dae Won, Kim, Won, Kim, Hyung Joon, Kim, Ji Hoon, Lee, Kwan Sik, Lee, Chun Kyon, Lim, Young-Suk, Park, Jun Yong, Tak, Won Young, Augustin, Salvador, Perez, Salvador Benlloch, Caballeria, Juan, Luis, Jose, Panero, Calleja, Rodríguez, Jose Carrión, Garcia, Javier Crespo, Samaniego, Javier Garcia, Gibert, Pere Ginès, Prieto, Martin, Gomez, Manuel Romero, Turnes, Juan, Dufour, Jean-Francois, Moriggia, Alberto, Sheen, I-Shyan, Kao, Jia-Horng, Cheng, Pin-Nan, Huang, Jee-Fu, Yang, Sheng-Shun, Su, Wei-Wen, Chen, Chi-Yi, Chien, Rong-Nan, Lo, Gin-Ho, Chu, Chi-Jen, Wang, Horng-Yuan, Hu, Jui-Ting, Huang, Yi Wen, Agarwal, Kosh, Allison, Michael, Anstee, Quentin, Austin, Andrew, Fowell, Andrew, Ch'ng, Chin Lye, Manousou, Pinelopi, Newsome, Philip, Ryder, Stephen, Shankar, Arun, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Alam, Imtiaz, Alba, Laura, Alkhouri, Naim, Allen, Alina, Aqel, Bashar, Balart, Luis, Barritt, A. Sidney, IV, Behari, Jaideep, Bennett, Michael, Bernstein, David, Bhandari, Bal Raj, Bonacini, Maurizio, Borg, Brian, Brown, Kimberly, Bzowej, Natalie, Caldwell, Stephen, Chami, Tawfik, Coates, Allan, Cueli, Adolfo, Davis, Mitchell, deLemos, Andrew, Desai, Archita, Dunn, Winston, Ferreira, Nelson, Fine, Michael, Firpi-Morell, Roberto, Freedland, Curtis, Freilich, Bradley, Fuchs, Michael, Galambos, Michael, Gallegos-Orozco, Juan, Galler, Greg, Ghali, Maged, Ghalib, Reem, Gill, Satinder, Gillis, Marcum, Gilroy, Richard, Gordon, Stuart, Gunn, Nadege, Halegoua-DeMarzio, Dina, Hassan, Mohamed, Hassanein, Tarek, Herring, Robert, Jr., Hong, John, Huang, Jonathan, Kabler, Heidi, Kayali, Zeid, Knapple, Whitfield, Kolli, Geetha, Kowdley, Kris, Krause, Richard, Lawitz, Eric, Lidofsky, Steven, Lim, Joseph, Lipkis, Donald, Loomba, Rohit, Mahgoub, Amar, Malespin, Miguel, Manch, Richard, Mannis, Steven, Manos, Paul, McDonald, Thomas, McKenzie, Mark, Mena, Edward, Merriman, Raphael, Moehlen, Martin William, Montgomery, Richard, Murphy, Robert, Natarajan, Yamini, Neff, Guy, Noureddin, Mazen, Ortiz-Lasanta, Grisell, Pagadala, Mangesh, Patel, Keyur, Patton, Heather, Peyton, Adam, Pimstone, Neville, Poulos, John, Pound, David, Pyrsopoulos, Nikolaos, Rafiq, Nila, Ravendhran, Natarajan, Ravinuthala, Ravi, Reddy, K. Rajendar, Reindollar, Robert, Reynolds, Justin, Rinella, Mary, Rizvi, Syed, Rockey, Don, Rodriguez-Perez, Federico, Ruane, Peter, Rubin, Raymond, Ryan, Michael, Saeian, Kia, Sanyal, Arun, Sarkar, Souvik, Scanga, Andrew, Schiff, Eugene, Schmidt, Warren, Schneider, Jeffrey, Sepe, Thomas, Shah, Dhiren, Shaikh, Obaid, Shankar, Uday, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shiffman, Mitchell, Siddique, Asma, Smith, Matthew, Suarez, Rosa, Talal, Andrew, Te, Helen, Tekola, Bezawit, Tetri, Brent, Thuluvath, Paul, Toro, Doris, Torres, Dawn, Trinh, Huy, Trotter, James, Vento, Angel, Vierling, John, Vuppalanchi, Raj, Waters, Michael, Weisberg, Ilan, Wieland, Amanda, Williams, Alonzo, Younes, Ziad, Adams, Leon, Harding, Damian, Hodge, Alex, Kontorinis, Nick, Strasser, Simone, Thompson, Alex, Horsmans, Yves, Steenkiste, Christophe Van, Bailey, Robert, Giard, Jeanne-Marie, Montano-Loza, Aldo, Puglia, Marco, Tsoi, Keith, Larrey, Dominique, Nguyen-Khac, Eric, Ratziu, Vlad, Spengler, Ulrich, Wiegand, Johannes, Hui, Aric Josun, Acharya, Subrat Kumar, Sarin, Shiv Kumar, Tantry, Vishwanath, Braun, Marius, Hazzan, Rawi, Lurie, Yoav, Colombo, Massimo, Fujii, Hideki, Hashimoto, Etsuko, Kato, Masaki, Ogawa, Koji, Takehara, Tetsuo, Tokushige, Katsutoshi, Garza, Laura Esthela Cisneros, Ladrón De Guevara, Alma Laura, Schultz, Michael, Janczewska, Ewa, Toro, Doris H., Jeong, Sook-Hyang, Kim, Yoon Jun, Lee, Jin-Woo, Ang, Tiing Leong, Bee, George Goh Boon, Benlloch, Salvador, Caballería, Juan, Calleja, José Luis, Rodríguez, Jose A. Carrión, Crespo, Javier, Diago, Moises, Fernandez-Rodriguez, Conrado, García-Samaniego, Javier, Ginès, Pere, Romero, Manuel, Dufour, Jean-François, Alazawi, William, Ch'ng, Chin-Lye, Forton, Daniel, Priest, Matthew, Sheridan, David, Ankoma-Sey, Victor, Balakrishnan, Maya, Bambha, Kiran, Barritt, A. Sidney, Bhandari, Bal, Brandman, Danielle, Chang, Charissa, Corey, Kathleen, Feldman, Michael, Gholam, Pierre, Goff, John, Marzio, Dina Halegoua-De, Harrison, Stephen, Hellstern, Paul, Jr., Herring, Robert, Iyer, Rajalakshmi, Jakiche, Antoine, Kohli, Anita, Krok, Karen, Kugelmas, Marcelo, Kumar, Sonal, Lai, Michelle, Mahmoud, Mitchell, Mantry, Parvez, Marsano, Luis, Nguyen, Tuan, Park, James, Patton, Heather M., Pockros, Paul, Reddy, Rajender, Rodriguez, Miguel, Sarles, Harry, Satapathy, Sanjaya, Sedghi, Shahriar, Shah, Nikunj, Sheikh, Muhammad Yasin, Sigal, Samuel, Stanca, Carmen, Steinbook, Michael, Szabo, Gyongyi, Terrault, Norah, Tong, Myron, Victor, David, Zervos, Xaralambos, Harrison, Stephen A., Wong, Vincent Wai-Sun, Caldwell, Stephen H., Shiffman, Mitchell L., Camargo, Marianne, Li, Georgia, Kersey, Kathryn, Jia, Catherine, Zhu, Yanni, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Anstee, Quentin M., Romero-Gomez, Manuel, Goodman, Zachary, Lawitz, Eric J., and Younossi, Zobair

Published
2020
Full Text
View/download PDF

4. Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders

Author

Cozen, Myrna L, Ryan, James C, Shen, Hui, Cheung, Ramsey, Kaplan, David E, Pocha, Christine, Brau, Norbert, Aytaman, Ayse, Schmidt, Warren N, Pedrosa, Marcos, Anand, Bhupinderjit S, Chang, Kyong-Mi, Morgan, Timothy, and Monto, Alexander

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hepatitis, Emerging Infectious Diseases, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Infectious Diseases, Rare Diseases, Substance Misuse, Clinical Research, Liver Disease, Hepatitis - C, Clinical Trials and Supportive Activities, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, Cohort Studies, Female, Hepatitis C, Humans, Interferon-alpha, Liver Cirrhosis, Male, Middle Aged, Proportional Hazards Models, Ribavirin, United States, United States Department of Veterans Affairs, Hepatitis C therapy, Cirrhosis, Hepatocellular carcinoma, Survival, Gastroenterology & Hepatology, Clinical sciences
Abstract

BackgroundAs the era of interferon-alpha (IFN)-based therapy for hepatitis C ends, long-term treatment outcomes are now being evaluated.AimTo more fully understand the natural history of hepatitis C infection by following a multisite cohort of patients.MethodsPatients with chronic HCV were prospectively enrolled in 1999-2000 from 11 VA medical centers and followed through retrospective medical record review.ResultsA total of 2211 patients were followed for an average of 8.5 years after enrollment. Thirty-one percent of patients received HCV antiviral therapy, 15 % with standard IFN/ribavirin only, 16 % with pegylated IFN/ribavirin, and 26.7 % of treated patients achieved sustained virologic response (SVR). Cirrhosis developed in 25.8 % of patients. Treatment nonresponders had a greater than twofold increase in the hazard of cirrhosis and hepatocellular carcinoma, compared to untreated patients, whereas SVR patients were only marginally protected from cirrhosis. Nearly 6 % developed hepatocellular carcinoma, and 27.1 % died during the follow-up period. Treated patients, regardless of response, had a significant survival benefit compared to untreated patients (HR 0.58, CI 0.46-0.72). Improved survival was also associated with college education, younger age, lower levels of alcohol consumption, and longer duration of medical service follow-up-factors typically associated with treatment eligibility.ConclusionsAs more hepatitis C patients are now being assessed for all-oral combination therapy, these results highlight that patient compliance and limiting harmful behaviors contribute a significant proportion of the survival benefit in treated patients and that the long-term clinical benefits of SVR may be less profound than previously reported.

Published
2016

12. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

Author

Poynard, Thierry, Colombo, Massimo, Bruix, Jordi, Schiff, Eugene, Terg, Ruben, Flamm, Steven, Moreno-Otero, Ricardo, Carrilho, Flair, Schmidt, Warren, Berg, Thomas, McGarrity, Thomas, Heathcote, E. Jenny, Gonçales, Fernando, Diago, Moises, Craxi, Antonio, Silva, Marcelo, Bedossa, Pierre, Mukhopadhyay, Pabak, Griffel, Louis, Burroughs, Margaret, Brass, Clifford, and Albrecht, Janice

Published
2009
Full Text
View/download PDF

24. Hepatitus C virus viremia in HIV-infected individuals with negative HCV antibody tests

Author

George, Sarah L., Gebhardt, Jenny, Klinzman, Donna, Foster, Mathew B., Patrick, Kevin D., Schmidt, Warren N., Alden, Beth, Pfaller, Michael A., and Stapleton, Jack T.

Subjects
Immunological research -- Analysis, Immunological research -- Statistics, HIV patients -- Health aspects, HIV patients -- Care and treatment, HIV infection -- Prevention, HIV infection -- Research, HIV infection -- Health aspects, Hepatitis C virus -- Causes of, Hepatitis C virus -- Care and treatment, Hepatitis C virus -- Prevention, Hepatitis C virus -- Health aspects, RNA -- Genetic aspects, Diabetes -- Health aspects, Health
Abstract

Research has been conducted on the hepatitis C virus (HCV) viremia. The characterization of this infection has been carried out via testing HIV-positive persons and HIV-negative control subjects with diabetes for the HCV antibody presence and HCV RNA and the results demonstrate that hepatitis C virus infection occurs more often among HIV-infected persons.

Published
2002

28. Zinc protoporphyrin binding to telomerase complexes and inhibition of telomerase activity.

Author

Zhaowen Zhu, Huy Tran, Huy, Mathahs, Meleah M., Fink, Brian D., Albert, John A., Moninger, Thomas O., Meier, Jeffery L., Ming Li, and Schmidt, Warren N.

Subjects
TELOMERASE, TELOMERASE reverse transcriptase, BIOFLUORESCENCE, ZINC-finger proteins, CONFOCAL fluorescence microscopy, DNA synthesis, CELL imaging
Abstract

Zinc protoporphyrin (ZnPP), a naturally occurring metalloprotoporphyrin (MPP), is currently under development as a chemotherapeutic agent although its mechanism is unclear. When tested against other MPPs, ZnPP was the most effective DNA synthesis and cellular proliferation inhibitor while promoting apoptosis in telomerase positive but not telomerase negative cells. Concurrently, ZnPP down-regulated telomerase expression and was the best overall inhibitor of telomerase activity in intact cells and cellular extracts with IC50 and EC50 values of ca 2.5 and 6 µM, respectively. The natural fluorescence properties of ZnPP enabled direct imaging in cellular fractions using non-denaturing agarose gel electrophoresis, western blots, and confocal fluorescence microscopy. ZnPP localized to large cellular complexes (>600 kD) that contained telomerase and dysskerin as confirmed with immunocomplex mobility shift, immunoprecipitation, and immunoblot analyses. Confocal fluorescence studies showed that ZnPP co-localized with telomerase reverse transcriptase (TERT) and telomeres in the nucleus of synchronized S-phase cells. Zn PP also co-localized with TERT in the perinuclear regions of log phase cells but did not co-localize with telomeres on the ends of metaphase chromosomes, a site known to be devoid of telomerase complexes. Overall, these results suggest that ZnPP does not bind to telomeric sequences per se, but alternatively, interacts with other structural components of the telomerase complex to inhibit telomerase activity. In conclusion, ZnPP actively interferes with telomerase activity in neoplastic cells, thus promoting pro-apoptotic and anti-proliferative properties. These data support further development of natural or synthetic protoporphyrins for use as chemotherapeutic agents to augment current treatment protocols for neoplastic disease. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection

Author

Bini, Edmund J., Bräu, Norbert, Currie, Sue, Shen, Hui, Anand, Bhupinderjit S., Hu, Ke-Qin, Jeffers, Lennox, Ho, Samuel B., Johnson, David, Schmidt, Warren N., King, Paul, Cheung, Ramsey, Morgan, Timothy R., Awad, Joseph, Pedrosa, Marcos, Chang, Kyong-Mi, Aytaman, Ayse, Simon, Franz, Hagedorn, Curt, Moseley, Richard, Ahmad, Jawad, Mendenhall, Charles, Waters, Bradford, Strader, Doris, Sasaki, Anna W., Rossi, Stephen, and Wright, Teresa L.

Published
2005

38. Values and the American manager: an update updated

Author

Posner, Barry Z. and Schmidt, Warren H.

Subjects
Corporations -- Social aspects, Executives -- Beliefs, opinions and attitudes, Social values -- Research, Corporate culture -- Social aspects, Business, Business, general
Abstract

'The direction and vitality of corporate America and its managers cannot be fully understood without knowing more about the values and visions of the men and women who manage it' is as true today as it was ten years ago when we originally reported on a nationwide survey of managers and their values. This study, involving 1,500 managers, replicates our earlier research and reveals that certain values are enduring (such as what we look for in leader), while other values are changing (such as how we balance personal and work demands). (Reprinted by permission of the publisher.)

Published
1992

39. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.

Author

Fuchs, Michael, Monto, Alexander, Bräu, Norbert, Charafeddine, Mariem, Schmidt, Warren, Kozal, Michael, Naggie, Susanna, Cheung, Ramsey, Schnell, Gretja, Yu, Yao, Richards, Kristine, Mullally, Victoria, Cohen, Daniel E., and Toro, Doris

Subjects
MENTAL illness, CHRONIC hepatitis C, HEPATITIS C virus, VETERANS, INFECTION
Abstract

Hepatitis C virus (HCV) infections are more common among US veterans receiving care through Veterans Affairs (VA) Medical Centers than among the general population. Historically, HCV therapies had lower efficacy rates in VA patients, possibly due to common comorbidities such as psychiatric disorders and substance abuse. The direct‐acting antivirals ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV)±ribavirin (RBV) are approved in the US for HCV genotype 1 (GT1)‐infected adults with or without cirrhosis. This study prospectively evaluated the safety and efficacy of OBV/PTV/r+DSV±RBV in VA patients with HCV GT1 infection. TOPAZ‐VA was a phase 3b, open‐label trial. Adult US veterans with HCV GT1 infection, without cirrhosis or with compensated cirrhosis, were eligible for enrollment. Patients with GT1a infection received OBV/PTV/r +DSV+RBV for 12 weeks or 24 weeks (for those with cirrhosis); GT1b‐infected patients without cirrhosis received OBV/PTV/r +DSV for 12 weeks; those with cirrhosis received OBV/PTV/r +DSV with RBV. The primary endpoint was sustained virologic response at posttreatment week 12 (SVR12); safety was also assessed. Ninety‐nine patients were enrolled at 10 sites from May through November 2015. The majority were male (96%), white (60%), and with GT1a infection (68%); 49% reported ongoing psychiatric disorders. Overall, 94% (93/99) achieved SVR12; three patients had a virologic failure. The most common AEs were fatigue (28%), headache (20%), and nausea (15%); six patients discontinued treatment due to AEs. In US veterans with HCV GT1 infection, OBV/PTV/r +DSV±RBV yielded a 94% overall SVR12 rate and was well tolerated. The presence of psychiatric disorders and/or injection drug use did not impact efficacy. Highlights: Chronic hepatitis C virus (HCV) infection occurs at a higher prevalence in the VA Health System than in the general population.These patients are also at a higher risk of psychiatric disorders and substance abuse, which were historically risk factors for successful treatment of HCV.We treated 99 patients in the VA Health System with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin for 12 to 24 weeks.Sustained virologic response was achieved in 93 of 99 patients, with safety and tolerability comparable to the general population.The presence of psychiatric or substance abuse disorders did not impact treatment success. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

46. Shared Values Make a Difference: An Empirical Test of Corporate Culture.

Author

Posner, Barry Z., Kouzes, James M., and Schmidt, Warren H.

Subjects
CORPORATE culture, SOCIOLOGY of corporations, PERSONNEL management, ORGANIZATIONAL behavior, ORGANIZATIONAL effectiveness, MANAGEMENT styles, INDUSTRIAL management, ORGANIZATIONAL goals, PROFESSIONAL relationships, CULTURAL values
Abstract

Is the recent popular management literature on corporate culture and cultural values just a passing fad or is it highlighting some fundamental organizational realities? The results from a recent nationwide survey of American managers shows, we are convinced, that clearly articulated organizational values do make a significant difference in the lives of employees, as well as in their organization's performance. This article is an effort to integrate this broad-based data on individual managers' values with the reported experience of successful organizations that pay careful attention to their culture. It also offers ideas on how human resource managers can facilitate the alignment of personal and organizational values. [ABSTRACT FROM AUTHOR]

Published
1985
Full Text
View/download PDF

47. DETERMINING MANAGERIAL STRATEGIES IN THE PUBLIC SECTOR: WHAT KIND OF PEOPLE ENTER THE PUBLIC AND PRIVATE SECTORS? AN UPDATED COMPARISON OF PERCEPTIONS, STEREOTYPES, AND VALUES.

Author

Posner, Barry Z. and Schmidt, Warren H.

Subjects
EMPLOYEE attitudes, PRIVATE sector, PUBLIC sector, BUSINESS enterprises, WORK environment, EMPLOYMENT
Abstract

The article presents a comparison of the perceptions of public and business employees. Many studies over the years have compared public sector employment with private sector employment. Within each sector strong negative stereotypes are generally expressed about counterparts in the other sector. Employees in each sector feel that while their jobs are difficult and important but at the same time feel that their counterparts in the other sector have it quite easy. Such beliefs have important social consequences. The negative stereotypes of government employees persists despite the evidence from several recent studies that there are no significant differences between managers in the public and private sectors on such critical dimensions as leadership styles, ability, personality role ambiguity and conflict, motivational orientation, work patterns or job characteristics. Other major source of potential differences between public and private sector management is in terms of situational, environmental, and organizational distinctions. The impact of the work environment as a contributing factor to public versus private sector employment choices, attitudes, and managerial strategies continues to warrant investigation.

Published
1982
Full Text
View/download PDF

50. Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.

Author

Bhattarai, Nirjal, McLinden, James H., Xiang, Jinhua, Mathahs, M. Meleah, Schmidt, Warren N., Kaufman, Thomas M., and Stapleton, Jack T.

Subjects
HEPATITIS C virus, VIRUS diseases, T cells, T cell receptors, SRC gene, PHOSPHATASES
Abstract

Among human RNA viruses, hepatitis C virus (HCV) is unusual in that it causes persistent infection in the majority of infected people. To establish persistence, HCV evades host innate and adaptive immune responses by multiple mechanisms. Recent studies identified virus genome-derived small RNAs (vsRNAs) in HCV-infected cells; however, their biological significance during human HCV infection is unknown. One such vsRNA arising from the hepatitis C virus (HCV) E2 coding region impairs T cell receptor (TCR) signaling by reducing expression of a Src-kinase regulatory phosphatase (PTPRE) in vitro. Since TCR signaling is a critical first step in T cell activation, differentiation, and effector function, its inhibition may contribute towards HCV persistence in vivo. The effect of HCV infection on PTPRE expression in vivo has not been examined. Here, we found that PTPRE levels were significantly reduced in liver tissue and peripheral blood mononuclear cells (PBMCs) obtained from HCV-infected humans compared to uninfected controls. Loss of PTPRE expression impaired antigen-specific TCR signaling, and curative HCV therapy restored PTPRE expression in PBMCs; restoring antigen-specific TCR signaling defects. The extent of PTPRE expression correlated with the amount of sequence complementarity between the HCV E2 vsRNA and the PTPRE 3’ UTR target sites. Transfection of a hepatocyte cell line with full-length HCV RNA or with synthetic HCV vsRNA duplexes inhibited PTPRE expression, recapitulating the in vivo observation. Together, these data demonstrate that HCV infection reduces PTPRE expression in the liver and PBMCs of infected humans, and suggest that the HCV E2 vsRNA is a novel viral factor that may contribute towards viral persistence. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results